Baird analyst Robert Mason lowered the firm’s price target on Novanta (NOVT) to $169 from $175 and keeps a Neutral rating on the shares. The firm said discrete customer decisions to defer ramps on new product intros, combined with capital goods demand softnes at year-end 2024 all contributing to revisions.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NOVT: